Release Date
Geography
Language of Resource
Full Text Available
Open Access / OK to Reproduce
Peer Reviewed
Objective
The study aims were to describe methamphetamine/amphetamine (MA/A) use among patients treated for OUD with buprenorphine/naloxone (BUP-NX) or extended-release naltrexone (XR-NTX), and to explore associations between treatment arm and MA/A use.
Findings/Key points
Among patients with treated opioid use disorder, nearly a fifth used methamphetamine/amphetamine (MA/A) baseline. Baseline use predicted future use, and MA/A use slightly increased over time. There was no significant difference in MA/A use in the BUP-NX v. XR-NTX treatment arms.
Design/methods
Secondary analysis of data from a multi-site, open-label, randomized controlled trial of XR-NTX versus BUP-NX for 24 weeks.